Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function ...

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope vs. placebo over two years1eGFR ...